Scopolamine ameliorates psoriasis by blocking M1 receptor–mediated IL-23 production in dendritic cells
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag179 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Yue Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shangha…. Hauptthemen laut MEDLINE: Psoriasis, Scopolamine, Dendritic Cells, Receptor, Muscarinic M1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China Original Exploration Program, National Natural Science Foundation of China Joint Fund, Shanghai Municipal Health Commission of Collaborative Innovation Cluster.
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin disease involving intricate neuroimmune crosstalk. However, the specific mechanisms and therapeutic targets remain elusive. In this study, a pilot clinical trial demonstrated that intravenous scopolamine, a muscarinic receptor antagonist, significantly ameliorated skin lesions in psoriasis patients. Consistently, scopolamine reduced inflammation in an imiquimod-induced mouse model. Metabolomic profiling identified acetylcholine (ACh) as a significantly upregulated neurotransmitter in psoriatic skin, and exogenous ACh exacerbated inflammatory phenotypes. To pinpoint the cellular target, single-cell RNA sequencing revealed that dendritic cells (DCs), unlike T cells or macrophages, uniquely coexpressed neurointeraction receptors and the pathogenic cytokine Il23a. Mechanistically, scopolamine competitively inhibited ACh binding to M1 muscarinic receptors (M1Rs) on DCs, suppressing interleukin (IL)-23 secretion. This therapeutic efficacy was recapitulated in mice with DC-specific M1R deletion. Crucially, the protective effect of M1R deficiency was abolished by recombinant IL-23 administration, whereas scopolamine failed to inhibit inflammation induced by direct IL-23 injection, confirming its action upstream of cytokine release. Collectively, our findings provide compelling evidence that scopolamine treats psoriasis by antagonizing elevated ACh and blocking M1 receptor-mediated IL-23 release in DCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine,…
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
- Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.
- Zhejiang University School of Medicine, Hangzhou, China.
- Department of Anesthesiology, Ruijin Hospital and Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Förderung
- National Natural Science Foundation of China Original Exploration Program
- National Natural Science Foundation of China Joint Fund
- Shanghai Municipal Health Commission of Collaborative Innovation Cluster
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
Zitieren
APA
Wu, Y., Zhang, Z., Cai, X., Sun, Y., Lou, F., Wang, Z., Li, Y., Zheng, X., Yang, X., Ding, W., Fang, Z., Zou, J., Xu, Z., Deng, S., Xu, A., Yu, B., Li, Q., & Wang, H. (2026). Scopolamine ameliorates psoriasis by blocking M1 receptor–mediated IL-23 production in dendritic cells. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag179
Vancouver
Wu Y, Zhang Z, Cai X, Sun Y, Lou F, Wang Z, et al. Scopolamine ameliorates psoriasis by blocking M1 receptor–mediated IL-23 production in dendritic cells. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag179
BibTeX
@article{Wu2026,
author = {Wu, Yue and Zhang, Ziyang and Cai, Xiaojie and Sun, Yang and Lou, Fangzhou and Wang, Zhikai and Li, Yan and Zheng, Xichen and Yang, Xiuli and Ding, Wenxiang and Fang, Zilong and Zou, Jing and Xu, Zhenyao and Deng, Siyu and Xu, Aie and Yu, Buwei and Li, Qifang and Wang, Honglin},
title = {Scopolamine ameliorates psoriasis by blocking M1 receptor–mediated IL-23 production in dendritic cells},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag179}
}
EUVIMED